DIFFERENCE OF TUMOR MASS IN STADIUM IIB-IIIB SQUAMOUS CELL CERVICAL CANCER PATIENTS WHO UNDERWENT PACLITAXEL CISPLATIN AND PACLITAXEL CARBOPLATIN CHEMOTHERAPY AT SANGLAH HOSPITAL DENPASAR
DOI:
https://doi.org/10.22159/ijpps.2017v9i11.21375Keywords:
Tumor mass, Cervical cancer, Chemotherapy, Paclitaxel cisplatin, Paclitaxel carboplatinAbstract
Objective: One of the parameters to measure the efficacy of the use of platinum based chemotherapy was the difference of tumor mass. Unfortunately, there was limited data about the use of rational chemotherapy medicine for cervical cancer patients at Sanglah Hospital. Therefore, research to find more data about the difference of tumor mass was necessary. Â
Method: A prospective observational research conducted at Sanglah Hospital from January until August 2016 by using consecutive sampling method. Patients qualified for the inclusive criteria were separated into two groups, paclitaxel cisplatin and paclitaxel carboplatin. Tumor mass data was gathered from before chemotherapy I and after chemotherapy VI by using USG 2D LOGIQ V5. Data analysed was performed with SPSS 20.0 for windows with a 95% confidence level using Wilcoxon test and Mann Whitney test.
Result: The mean value of tumor mass for patients in paclitaxel cisplatin regimen group before chemotherapy I and after chemotherapy VI were 68.91+7.41 cm3 and 10.62+6.82 cm3 respectively (p value=0.018). The mean value of tumor mass for patients in paclitaxel carboplatin regimen group before chemotherapy I and after chemotherapy VI were 53.44+52.25 cm3 and 9.18 + 8.23 cm3 respectively (p value=0.007). Meanwhile, the mean value of difference in tumor mass in paclitaxel cisplatin and paclitaxel carboplatin group was -58.29 + 49.93 cm3 and -44.26 + 51.48 cm3 respectively (p value=0.242).      Â
Conclusion: This research shows that there was a significant difference of tumor mass before chemotherapy I and chemotherapy VI in both regimen groups. There was a bigger decrease of tumor mass in patients from paclitaxel cisplatin chemotherapy group compared to paclitaxel carboplatin group, but not significantly different.Â
Downloads
References
GLOBOCAN. Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. France: International Agency for Research on Cancer (IARC); 2012.
Elit LM, Hirte H. Management of advanced or recurrent cervical cancer: chemotherapy and beyond. Expert Rev Anticancer Ther 2014;14:319-32.
Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 Suppl 7:vii27-32.
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 2014;740:364-78.
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004;22:3113-9.
Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin dan paclitaxel for advanced and recurrent cervical carcinoma: the brithis columbia cancer agency experience. J Gynecol Oncol 2005;98:54-8.
Noviyani R, Suwiyoga K, Budiana ING, Tunas K, Indrayathi PA. Effectiveness and toxicity differences between the use of regimen-chemotherapy bleomycin-vincristine-mitomycin-cisplatin and bleomycin-vincristine-mitomycin-carboplatin for three cycles in patients cervical cancersquamous cell stadium IIB-IIIB in sanglah general hospital denpasar bali. Asian J Pharm Clin Res 2016;9 Suppl 2:149-53.
Perry MC. The chemotherapy source book. Colombia: Lippincott William and Wilkins; 2008.
Furie B, Cassileth PA, Atkins MB, Mayer RJ. Clinical hematology and oncology presentation, diagnosis and treatment. United States: Churchill Livingston and Imprint of Elsevier; 2003.
Komite Medik. Prosedur tetap kemoterapi kanker serviks. Denpasar: Rumah Sakit Umum Pusat Sanglah; 2011.
WHO (World Health Organization). Comprehensive cervical cancer control a guide to essential practice. Switzerland: World Health Organization; 2014.
Alves C, Alves L, Lunet N. Epidemiology of cervical cancer. Arquivos De Midicina 2010;24:266-77.
Pandey D, Shetty J, Sambhaji C, Saxena PU, Mishra D, Chawla A. Cervical cancer as a silent killer: a rare case report. J Can Res Ther 2015;11:653.
Mandic A. Neoadjuvant chemotherapy in treatment of cervical cancer–controversies. Arch Oncol 2005;13:89-90.
Aziz F, Andrijono, Saifuddin AB. Buku acuan nasional onkologi ginekologi. Jakarta: Yayasan Bina Pustaka Sarwono Prawirohardjo; 2006. p. 359-442.
Miller T, Perry G. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2002;53:353-9.
Airley R. Chemotherapy cancer basic science to the clinic. Great Britain: John Wiley and Sons Ltd; 2009. p. 55-8.
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol 2009;27:4649-55.
Garces AHI, Mora PAR, Alves FPG, Carmo CC, Grazziotin R, Fernandes ACFM, et al. First-line paclitaxel and carboplatin inpersistent/recurrent or advanced cervical cancer a retrospective analysis of patients treated at Brazilian National Cancer Institute. Int J Gynecol Cancer 2013;23:743-8.
Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer d the addenbrooke’s experience. Clin Oncol 2008;20:358-64.
Noviyani R, Suwiyoga K, LesmanaI, Niruri R, Tunas K, Budiana ING. Differences of tumor masses and hemoglobin levels incervical cancer squamous cell type patients treatedwith combination of paclitaxel and carboplatinchemotherapy. Br Med J 2014;3:15-7.
Rossi A, Chiodini P, Sun JM, O’Brien MER, Plessen CV, Barata F, et al. Six versus fewer planned cycles of first-line platinum-basedchemotherapy for non-small-cell lung cancer: a systematicreview and meta-analysis of individual patient data. Lancet Oncol 2014;15:1254–62.
Angioli R, Plotti F, Aloisi A, Scaletta G, Capriglione S, Luvero D, et al. A randomized controlled trial comparing four versussix courses of adjuvant platinum-based chemotherapy inlocally advanced cervical cancer patients previouslytreated with neo-adjuvant chemotherapy plus radicalsurgery. Gynecol Oncol 2015;199:433-8.
Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015;33:1-7.
Moore NK, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007;105:299–303.
Published
How to Cite
Issue
Section
